CompletedNot Applicable

A Study to Evaluate the Use of Cidofovir (an Experimental Drug) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in AIDS Patients

United States24 participants

Plain-language summary

The purpose of this study is to evaluate the safety, tolerance, and overall effectiveness of cidovir to treat PML in AIDS patients. PML is an opportunistic infection (HIV-associated, due to weak immune system) caused by a virus that attacks the brain. Cidovir has been used effectively to treat cytomegalovirus (CMV) of the eye. Cidovir could be an effective treatment for PML as well.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria You may be eligible for this study if you: * Are HIV-positive. * Have had symptoms of PML for no more than 90 days before study entry, or have had abnormal neurological exams related to PML. * Have negative tests for bacterial or fungal infections. * Agree to practice abstinence or use effective methods of birth control during the study. * Are at least 18 years old. * Have a life expectancy of at least 6 months. Exclusion Criteria You will not be eligible for this study if you: * Have a history of uveitis. * Are allergic to sulfa drugs or probenecid. * Have had active opportunistic infections other than Kaposi's sarcoma within 30 days before study entry. * Have sickle cell anemia or trait. * Are pregnant or breast-feeding.

Trial details

NCT IDNCT00000945

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)

Sponsor typeNIH

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More HIV Infections trials